Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and mdv 3100

sorafenib has been researched along with mdv 3100 in 4 studies

Compound Research Comparison

Studies
(sorafenib)		Trials
(sorafenib)		Recent Studies (post-2010)
(sorafenib)		Studies
(mdv 3100)		Trials
(mdv 3100)		Recent Studies (post-2010) (mdv 3100)
6,5207305,2511,5461821,502

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)mdv 3100 (IC50)
Gamma-aminobutyric acid receptor subunit piHomo sapiens (human)3
Gamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)3
Prostate-specific antigenHomo sapiens (human)0.13
Androgen receptorHomo sapiens (human)0.8644
Gamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)3
Androgen receptorRattus norvegicus (Norway rat)0.8238
Gamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)3
Gamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)3
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)1.26
Gamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)3
Gamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)3
Gamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)3
Gamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)3
Gamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)3
Gamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)3
Gamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)3
Gamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)3
Gamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)3
Gamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)3
Gamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)3

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (50.00)24.3611
2020's2 (50.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Bian, J; Cheng, Y; Duan, J; Gao, X; Wu, H; Yang, Y; You, L; Zhang, L; Zhang, X; Zhu, Q1
Abou-Alfa, GK; Boussayoud, C; Capanu, M; Chou, JF; Do, GK; El Dika, I; Ferrer, CS; Harding, JJ; Iyer, R; Kelley, RK; Khalil, DN; Kuhn, P; Muenkel, K; Rodriguez-Lee, M; Ruiz, C; Shia, J; Tan, B; Wilton, J; Yarmohammadi, H1
Daniele, B; Lim, HY; López, B; Palmer, DH; Park, SR; Rimassa, L; Ryoo, BY; Steinberg, J1

Trials

2 trial(s) available for sorafenib and mdv 3100

ArticleYear
Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
    The oncologist, 2020, Volume: 25, Issue:12

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Nitriles; Phenylthiohydantoin; Phenylurea Compounds; Sorafenib; Treatment Outcome

2020
Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma.
    Clinical drug investigation, 2021, Volume: 41, Issue:9

    Topics: Benzamides; Carcinoma, Hepatocellular; Double-Blind Method; Humans; Liver Neoplasms; Nitriles; Phenylthiohydantoin; Sorafenib

2021

Other Studies

2 other study(ies) available for sorafenib and mdv 3100

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.
    Cancer letters, 2017, 01-28, Volume: 385

    Topics: Androgen Antagonists; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Nitriles; Phenylthiohydantoin; Phenylurea Compounds; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Receptors, Androgen; Signal Transduction; Sorafenib; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays

2017